Biotechnology M&A » By The Online Investor Staff, updated Thu., May. 9, 9:01 AM
Recent mergers and acquisitions in the Biotechnology M&A category.
Slide #39. Grifols — Transfusion diagnostics unit of Novartis
Acquirer: |
Grifols (GRFS) |
Acquiree: |
Transfusion diagnostics unit of Novartis (NVS) |
Details: |
Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a global healthcare company and leading producer of plasma therapies, and Novartis (VX: NOVN, NYSE: NVS), today announced that they have signed a definitive agreement whereby Grifols will acquire the transfusion diagnostics unit of Novartis for a total amount of US$1,675 million (1,240 million). |
Grifols is a global pharmaceutical company developing, manufacturing and distributing a range of biological medicines based on plasma derived proteins. Co. organizes its business into several divisions, including: Bioscience, which includes activities relating to the manufacture of plasma derivatives for therapeutic use, and the sale and distribution of end products; Diagnostic, which focuses on researching, developing, manufacturing and marketing in vitro diagnostics products; Hospital, which provides technology and services for hospitals, clinics and other centers for the manufacture of medicines; and Bio Supplies, which primarily consists of biological products for non-therapeutic use.
Open the GRFS Page at The Online Investor »
Grifols is a global pharmaceutical company developing, manufacturing and distributing a range of biological medicines based on plasma derived proteins. Co. organizes its business into several divisions, including: Bioscience, which includes activities relating to the manufacture of plasma derivatives for therapeutic use, and the sale and distribution of end products; Diagnostic, which focuses on researching, developing, manufacturing and marketing in vitro diagnostics products; Hospital, which provides technology and services for hospitals, clinics and other centers for the manufacture of medicines; and Bio Supplies, which primarily consists of biological products for non-therapeutic use.
Open the NVS Page at The Online Investor »
Company Name: |
Grifols SA, Barcelona |
Website: |
www.grifols.com |
Sector: |
Biotechnology |
Number of ETFs Holding GRFS: |
4 |
Total Market Value Held by ETFs: |
$2.97M |
|
Company Name: |
Novartis AG Basel |
Website: |
www.novartis.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding NVS: |
5 |
Total Market Value Held by ETFs: |
$114.62M |
Total Market Capitalization: |
$290.92B |
% of Market Cap. Held by ETFs: |
0.04% |
|